 |
市場調査レポート
商品コード
1447788
甲状腺疾患治療の世界市場規模、シェア、成長分析、治療方法別、エンドユーザー別 - 産業予測2024～2031年Global Thyroid Gland Disorders Treatment Market Size, Share, Growth Analysis, By Treatment Methods(Medication, Radioiodine therapy), By End-users(Hospitals, Clinics) - Industry Forecast 2024-2031 |
||||||
| 甲状腺疾患治療の世界市場規模、シェア、成長分析、治療方法別、エンドユーザー別 - 産業予測2024～2031年 |
|
出版日: 2024年02月26日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の甲状腺疾患治療の市場規模は、2022年に23億7,000万米ドルとなり、2023年の24億5,000万米ドルから、2031年までには31億4,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは3.17％で成長する見通しです。
甲状腺疾患治療の世界市場は近年著しい成長を遂げており、これは主に甲状腺機能亢進症のような疾患の世界の有病率の増加によるものです。人口の高齢化、医療技術の進歩、早期診断・治療の重視の高まりなどの要因が、この拡大に寄与しています。さらに、特定の甲状腺問題に合わせた新しいカスタマイズ医療技術や標的薬の導入が、市場情勢を豊かにしています。北米と欧州は甲状腺疾患の罹患率が高く、医療費も高いため、現在この市場を独占していますが、ラテンアメリカとアジア太平洋の新興国は、医療インフラの改善と意識の高まりにより、有望な成長の可能性を示しています。限られた診断施設や高額な治療費といった課題にもかかわらず、遠隔医療と遠隔モニタリング・ソリューションの統合は、特に医療が行き届いていない地域において、甲状腺医療へのアクセス拡大を促進しています。こうした障害は成長の妨げになるかもしれませんが、世界の甲状腺疾患治療市場の予測される軌道は、回復力と継続的な拡大を示唆しています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
甲状腺疾患治療の世界市場：治療法別
- 市場概要
- 投薬治療
- 放射性ヨウ素療法
- 甲状腺切除術
- 代替療法
甲状腺疾患治療の世界市場：エンドユーザー別
- 市場概要
- 病院
- クリニック
- 小売薬局
甲状腺疾患治療の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- AbbVie Inc.（United States）
- Merck & Co., Inc.（United States）
- Eli Lilly and Company（United States）
- Abbott Laboratories（United States）
- Sanofi（France）
- Boehringer Ingelheim（Germany）
- Takeda Pharmaceutical Company Limited（Japan）
- Bayer AG（Germany）
- Mylan N.V.（Netherlands）
- Fresenius Kabi AG（Germany）
- Bristol-Myers Squibb Company（United States）
- Novartis International AG（Switzerland）
- GlaxoSmithKline plc（United Kingdom）
- Johnson & Johnson（United States）
- Amgen Inc.（United States）
- AstraZeneca（United Kingdom）
- Cipla Ltd.（India）
- Pfizer Inc.（United States）
- Sun Pharmaceutical Industries Ltd.（India）
- Teva Pharmaceutical Industries Ltd.（Israel）
Global Thyroid Gland Disorders Treatment Market size was valued at USD 2.37 billion in 2022 and is poised to grow from USD 2.45 billion in 2023 to USD 3.14 billion by 2031, growing at a CAGR of 3.17% in the forecast period (2024-2031).
The global market for treating thyroid gland disorders has experienced significant growth in recent years, largely driven by the increasing prevalence of conditions like hyperthyroidism worldwide. Factors such as aging populations, advancements in medical technology, and a growing emphasis on early diagnosis and treatment have contributed to this expansion. Furthermore, the introduction of new customized medicine techniques and targeted medications tailored to specific thyroid issues has enriched the market landscape. While North America and Europe currently dominate this market due to higher rates of thyroid disorders and healthcare expenditures, emerging economies in Latin America and Asia-Pacific exhibit promising growth potential due to improving healthcare infrastructure and rising awareness. Despite challenges such as limited diagnostic facilities and high therapy costs, the integration of telemedicine and remote monitoring solutions, particularly in underserved areas, has facilitated greater access to thyroid care. Although these obstacles may hinder growth, the projected trajectory of the global thyroid gland disorders treatment market suggests resilience and continued expansion.
Top-down and bottom-up approaches were used to estimate and validate the size of the Thyroid Gland Disorders Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Thyroid Gland Disorders Treatment Market Segmental Analysis
Market segmentation based on treatment methods includes medication, radioiodine therapy, thyroidectomy, and alternative therapies. When the market is divided based on end-users, it includes hospitals, clinics, and retail pharmacies. Geographically, the market can be divided into North America, Europe, Asia-Pacific, and the rest of the world.
Drivers of the Thyroid Gland Disorders Treatment Market
The global market for treating thyroid disorders is experiencing notable growth, propelled by the escalating prevalence of conditions such as hyperthyroidism, hypothyroidism, and thyroid cancer worldwide. Factors contributing to this rise include heightened mental stressors impacting lifestyles and environmental influences. Consequently, there has been a surge in demand for treatments targeting thyroid gland issues. Advancements in medical research and technology have significantly enriched the market with a plethora of innovative therapy options, including novel drugs, targeted therapies, and minimally invasive surgical procedures.
Restraints in the Thyroid Gland Disorders Treatment Market
Despite these advancements, challenges such as the exorbitant cost of medications and treatments, particularly for long-term therapies, pose a significant barrier to accessibility, especially for patients in underserved areas with limited healthcare access or inadequate insurance coverage. Moreover, the scarcity of diagnostic facilities and low awareness about thyroid health in certain regions hinder early detection and treatment initiation, potentially impacting patient outcomes and survival rates.
Market Trends of the Thyroid Gland Disorders Treatment Market
Market trends reflect a proactive response to these challenges, with increased investment in research and development by pharmaceutical companies to develop more effective and affordable treatment options. Additionally, the market is witnessing a growing emphasis on diversifying treatment modalities in response to the rising incidence of thyroid disorders globally, driven by lifestyle changes, improved diagnostic capabilities, and dietary shifts. As a result, demand for surgical interventions, medications, and radioactive iodine therapy is on the rise, underscoring the expanding scope of the thyroid disorder treatment market.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Thyroid Gland Disorders Treatment Market by Treatment Methods
- Market Overview
- Medication
- Radioiodine therapy
- Thyroidectomy
- and Alternative therapies
Global Thyroid Gland Disorders Treatment Market by End-users
- Market Overview
- Hospitals
- Clinics
- and Retail Pharmacies
Global Thyroid Gland Disorders Treatment Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (United States))
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany))
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis International AG (Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (United States
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
